Kenvue Inc. (NYSE:KVUE) Shares Bought by Kennon Green & Company LLC

Kennon Green & Company LLC raised its stake in Kenvue Inc. (NYSE:KVUE) by 0.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 171,535 shares of the company’s stock after acquiring an additional 1,513 shares during the quarter. Kenvue makes up 3.2% of Kennon Green & Company LLC’s portfolio, making the stock its 11th biggest holding. Kennon Green & Company LLC’s holdings in Kenvue were worth $3,662,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the stock. Huntington National Bank boosted its position in shares of Kenvue by 26.5% in the third quarter. Huntington National Bank now owns 4,161 shares of the company’s stock worth $96,000 after buying an additional 871 shares during the period. ING Groep NV boosted its holdings in Kenvue by 23.6% in the third quarter. ING Groep NV now owns 3,576,616 shares of the company’s stock valued at $82,727,000 after purchasing an additional 681,954 shares during the last quarter. Golden State Equity Partners boosted its holdings in Kenvue by 716.1% in the fourth quarter. Golden State Equity Partners now owns 25,658 shares of the company’s stock valued at $548,000 after purchasing an additional 22,514 shares during the last quarter. Empower Advisory Group LLC purchased a new position in Kenvue in the fourth quarter valued at about $48,252,000. Finally, Everence Capital Management Inc. boosted its holdings in Kenvue by 122.1% in the fourth quarter. Everence Capital Management Inc. now owns 45,380 shares of the company’s stock valued at $969,000 after purchasing an additional 24,950 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Price Performance

KVUE opened at $23.31 on Friday. The stock has a market cap of $44.68 billion, a price-to-earnings ratio of 43.97, a PEG ratio of 2.61 and a beta of 1.45. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a fifty day moving average price of $21.29 and a 200 day moving average price of $22.14.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be issued a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.52%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s payout ratio is currently 154.72%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on KVUE. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and cut their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Royal Bank of Canada restated a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Citigroup cut their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Canaccord Genuity Group cut their price objective on Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Finally, Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $21.00 to $26.00 in a research note on Monday, January 6th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $23.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.